AAPL 195.95 -0.4 (-0.20%)MSFT 133.45 +0.52 (+0.39%)FB 188.78 +0.08 (+0.04%)ZNGA 5.91 -0.04 (-0.59%)NVDA 151.96 -0.17 (-0.11%)WBA 53.16 +0.06 (+0.12%)GOOG 1086.06 +0.02 (+0.00%)PIH 5.3 0 (0.00%)
AAPL 195.95 -0.4 (-0.20%)MSFT 133.45 +0.52 (+0.39%)FB 188.78 +0.08 (+0.04%)ZNGA 5.91 -0.04 (-0.59%)NVDA 151.96 -0.17 (-0.11%)WBA 53.16 +0.06 (+0.12%)GOOG 1086.06 +0.02 (+0.00%)PIH 5.3 0 (0.00%)

Financial Statements CRSP Quote CRISPR Ther

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Income Statement
Year 20142015201620172018
Revenue 0 0 0 0 0
COGS 0 0 0 0 0
GrossProfit 0 0 0 5 41
Depreciation (included in COGS) 0 0 0 0 0
StockBasedCompe (included in COGS) 0 1 4 11 19
ResearchAndDeve 0 2 13 42 70
SalesGeneralAnd 0 5 13 31 36
OperatingIncome 0 -7 -26 -68 -65
InterestExpense 0 0 0 8 0
OtherIncome 0 0 0 53 -2
IncomeBeforeTax 0 -7 -26 -23 -67
ProvisionForInc 0 0 0 0 0
NetIncome 0 -6 -26 -23 -68
Balance Sheet
Year 20142015201620172018
CashAndCashEqui 0 1 156 316 240
ShortTermInvest 0 0 0 0 0
Cash 0 1 156 0 0
AccountReceivab 0 0 0 0 0
Inventories 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
OtherCurrentAss 0 0 0 1 0
TotalCurrentAss 0 1 157 320 248
PPE 0 0 1 22 23
AccumulatedDepr 0 0 0 -1 -4
NetPPE 0 0 1 21 19
EquityAndOtherI 0 0 0 0 0
Goodwill 0 0 0 0 0
IntangibleAsset 0 1 0 0 0
OtherLTAssets 0 0 1 3 4
TotalNonCurrent 0 1 3 25 23
TotalAssets 0 2 159 345 271
ShortTermDebt 0 0 0 0 0
AccountsPayable 0 0 2 0 0
TaxesPayable 0 0 0 0 0
AccruedLiabilit 0 2 8 0 0
DeferredRevenue 0 0 75 78 57
OtherCurrentLia 0 0 0 1 1
TotalCurrentLia 0 2 10 22 15
Debt 0 0 38 0 0
DeferredTaxesLi 0 0 0 0 0
DeferredRevenue 0 0 0 0 0
OtherLTLiabilit 0 6 65 12 12
TotalNonCurrent 0 6 178 90 69
TotalLiabilitie 0 9 189 112 84
CommonStock 0 0 0 1 1
AdditionalPaidI 0 1 5 289 312
RetainedEarning 0 -8 -34 -57 -125
AccumulatedOthe 0 0 0 0 0
TotalStockholde 0 -7 -29 233 188
TotalLiabilitie 0 2 159 345 271
Cash Flow Statement
Year 20142015201620172018
NetIncome 0 -6 -26 -23 -68
Depreciation 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
StockBasedCompe 0 1 4 11 19
AccountsReceiva 0 0 0 -3 1
InventoryCS 0 0 0 0 0
AccountsPayable 0 0 0 0 0
OtherWorkingCap 0 2 82 6 -22
OtherNonCashIte 0 0 0 -46 2
NetCashProvided 0 -5 59 -55 -70
InvestmentsInPP 0 0 -1 -3 -8
AcquisitionsNet 0 0 0 0 0
PurchasesOfInve 0 0 0 0 0
SalesMaturities 0 0 0 0 0
PurchasesOfInta 0 0 0 0 0
OtherInvestingA 0 0 0 35 0
NetCashUsedForI 0 0 -1 32 -8
DebtIssued 0 0 38 35 0
DebtRepayment 0 0 0 0 0
CommonStockIssu 0 0 0 89 0
CommonStockRepu 0 0 0 0 0
DividendPaid 0 0 0 0 0
OtherFinancingA 0 0 0 -2 3
NetCashProvided 0 5 97 183 3
NetChangeInCash 0 1 155 160 -76
CashAtBeginning 0 0 1 156 316
CashAtEndOfPeri 0 1 156 316 240
Retained Earnings
Year 20142015201620172018
RetainedEarning -----8
NetIncome ----6-26
StockDividend ---1452
DividendPaid -----
RetainedEarning ----8-34
Property Plant and Equipment Schedule
Year 20142015201620172018
NetPPE -----
DeprAnnual 0----
CapitalExpendit 00001
NetPPE ----1
Intangible and Goodwill Schedule
Year 20142015201620172018
intAndGW 0---1
Amortization 0----
NewPurchases 0--1-1
intAndGW ---1-
CRISPR Therapeutics AG income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes CRISPR Therapeutics AG FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.